IL137428A0 - Estrogen agonists and antagonists for multiple indications - Google Patents

Estrogen agonists and antagonists for multiple indications

Info

Publication number
IL137428A0
IL137428A0 IL13742800A IL13742800A IL137428A0 IL 137428 A0 IL137428 A0 IL 137428A0 IL 13742800 A IL13742800 A IL 13742800A IL 13742800 A IL13742800 A IL 13742800A IL 137428 A0 IL137428 A0 IL 137428A0
Authority
IL
Israel
Prior art keywords
antagonists
estrogen agonists
multiple indications
indications
estrogen
Prior art date
Application number
IL13742800A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL137428A0 publication Critical patent/IL137428A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13742800A 1999-07-28 2000-07-20 Estrogen agonists and antagonists for multiple indications IL137428A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14607299P 1999-07-28 1999-07-28
US14607599P 1999-07-28 1999-07-28

Publications (1)

Publication Number Publication Date
IL137428A0 true IL137428A0 (en) 2001-07-24

Family

ID=26843545

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13742800A IL137428A0 (en) 1999-07-28 2000-07-20 Estrogen agonists and antagonists for multiple indications

Country Status (9)

Country Link
EP (1) EP1086692A3 (ko)
JP (1) JP2001048805A (ko)
KR (1) KR20010049909A (ko)
AU (1) AU4882700A (ko)
CA (1) CA2314572A1 (ko)
HU (1) HUP0002979A2 (ko)
IL (1) IL137428A0 (ko)
NZ (1) NZ506014A (ko)
PE (1) PE20010347A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436977B1 (en) 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
GB2475907A (en) * 2009-12-04 2011-06-08 Tcp Innovations Ltd Composition comprising a mixture of clopidogrel and droloxifene
BR112019007254A2 (pt) 2016-10-11 2019-07-02 Univ Duke tratamento lasofoxifeno de câncer de mama er+
US20190231743A1 (en) * 2016-10-11 2019-08-01 Sermonix Pharmaceuticals, Llc Lasofoxifene treatment of vva and osteoporosis in survivors of breast cancer and other malignancies
CN112261937B (zh) 2018-04-10 2023-11-14 杜克大学 乳腺癌的拉索昔芬治疗

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis

Also Published As

Publication number Publication date
HUP0002979A2 (hu) 2002-04-29
HU0002979D0 (en) 2000-10-28
EP1086692A3 (en) 2003-07-09
KR20010049909A (ko) 2001-06-15
NZ506014A (en) 2001-11-30
EP1086692A2 (en) 2001-03-28
JP2001048805A (ja) 2001-02-20
AU4882700A (en) 2001-02-01
CA2314572A1 (en) 2001-01-28
PE20010347A1 (es) 2001-03-23

Similar Documents

Publication Publication Date Title
EG23913A (en) Estrogen agonists / antagonists
IL150898A0 (en) Novel melanocortin receptor agonists and antagonists
HK1124339A1 (en) 20-keto-11beta-arylsteroids and their derivatives having agonist or antagonist hormonal activity 20--11-
AP2000001916A0 (en) 2-Adrenergic receptor agonists
AU1772300A (en) Glucagon antagonists/inverse agonists
HK1039963A1 (en) Il-2 selective agonists and antagonists
PL352127A1 (en) Dispersion probe
IL141050A0 (en) Muscarinic agonists and antagonists
AUPP380498A0 (en) Egf receptor agonists and antagonists
GB2368641B (en) Methods and compositions for assaying analytes
EP1299410A4 (en) SPECIFIC AGONISTS FOR GRFalpha1-RET AND RELATED METHODS
GB9807075D0 (en) Endometrial samplers
EP1242074A4 (en) NMDA / NR2B ANTAGONISTS BASED ON 5-BENZYL-OCTAHYDROINDOLE AND 6-BENZYL-DECAHYDROQUINOLINE
HU0002979D0 (en) Estrogen agonists and antagonists for multiple indications
AU5861900A (en) Receptor agonists and antagonists
IL146941A0 (en) Somatostain agonists
GB9820014D0 (en) Receptor antagonists and uses thereof
HU9902674D0 (en) Estrogen agonists/antagonists
IL144355A0 (en) 5-ht1f agonists
HUP0301384A3 (en) Urotensin-ii agonists and antagonists
GB9902062D0 (en) Mail location apparatus
AUPP259898A0 (en) EGF receptor family agonists and antagonists
GB9920388D0 (en) Hepato-selective glucocorticoid antagonists
AUPP058597A0 (en) Receptor agonists and antagonists
GB9908235D0 (en) Estrogen receptors and bone